APA (7th ed.) Citation

de Winter, R. J., Katagiri, Y., Asano, T., Milewski, K. P., Lurz, P., Buszman, P., . . . Goube, P. (2018). A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): A randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet, 391(10119), 431. https://doi.org/10.1016/S0140-6736(17)33103-3

Chicago Style (17th ed.) Citation

de Winter, Robbert J., et al. "A Sirolimus-eluting Bioabsorbable Polymer-coated Stent (MiStent) Versus an Everolimus-eluting Durable Polymer Stent (Xience) After Percutaneous Coronary Intervention (DESSOLVE III): A Randomised, Single-blind, Multicentre, Non-inferiority, Phase 3 Trial." Lancet 391, no. 10119 (2018): 431. https://doi.org/10.1016/S0140-6736(17)33103-3.

MLA (9th ed.) Citation

de Winter, Robbert J., et al. "A Sirolimus-eluting Bioabsorbable Polymer-coated Stent (MiStent) Versus an Everolimus-eluting Durable Polymer Stent (Xience) After Percutaneous Coronary Intervention (DESSOLVE III): A Randomised, Single-blind, Multicentre, Non-inferiority, Phase 3 Trial." Lancet, vol. 391, no. 10119, 2018, p. 431, https://doi.org/10.1016/S0140-6736(17)33103-3.